Onconova Gets up to $565M in Phase III MDS Baxter Deal
BioWorld Today Contributing Writer
Onconova Therapeutics Inc.'s deal with Baxter International Inc. for European rights to rigosertib for myelodysplastic syndromes (MDS) and pancreatic cancer, worth up to $565 million, tops off a string of agreements over the past few years that leaves the company with full U.S. ownership of the late-stage compound.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST